共 50 条
- [1] Adverse events in real-world patients covered by Medicare with metastatic pancreatic ductal adenocarcinoma who received first-line FOLFIRINOXJOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)Dieguez, GabrielaTomicki, SamanthaCockrum, PaulHirsch, JaredBhatt, PrachiKim, George P.
- [2] Dosing patterns and treatment patterns in real-world patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) who received FOLFIRINOX in the first lineJOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)MacEwan, Joanna P.Silver, MichelleCockrum, PaulSanders, ChadKim, George P.
- [3] Patterns of treatment switching and healthcare resource utilization differences among real-world Medicare patients with metastatic pancreatic ductal adenocarcinoma who received first-line FOLFIRINOXJOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)Dieguez, GabrielaHirsch, JaredCockrum, PaulBhatt, PrachiTomicki, SamanthaKim, George P.
- [4] Real-world overall survival and time to next treatment in patients with metastatic pancreatic ductal adenocarcinoma who received FOLFIRINOX and modified FOLFIRINOX in the first line.JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 629 - 629Dennen, SyvartBoppudi Naga, Sai SritejaCockrum, PaulPaluri, Ravi Kumar
- [5] First-line treatment patterns among patients with metastatic pancreatic ductal adenocarcinoma in the real-world settingJOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)Dennen, SyvartHarton, JoannaCockrum, PaulKim, George P.MacEwan, Joanna P.
- [6] Components of total cost of care in real-world patients with mPDAC who received first-line FOLFIRINOX or Gem/AbraxJOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)Hirsch, JaredCockrum, PaulTomicki, SamanthaDieguez, GabrielaBhatt, PrachiKim, George P.
- [7] De-escalation and dose density in real-world patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) who received FOLFIRINOX in the first line.JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 628 - 628Dennen, SyvartShao, AnranDennen, SyvartCockrum, PaulPaluri, Ravi Kumar
- [8] Adverse events in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) who received FOLFIRINOX in the first lineJOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)Kim, George P.Silver, MichelleSanders, ChadCockrum, PaulMacEwan, Joanna P.Duncan, Dan
- [9] Treatment Patterns in US Patients Receiving First-Line and Second-Line Therapy for Metastatic Pancreatic Ductal Adenocarcinoma in the Real WorldADVANCES IN THERAPY, 2022, 39 (12) : 5433 - 5452King, GentryIttershagen, StacieHe, LuyangShen, YingLi, FrankVillacorta, Reginald
- [10] Treatment Patterns in US Patients Receiving First-Line and Second-Line Therapy for Metastatic Pancreatic Ductal Adenocarcinoma in the Real WorldAdvances in Therapy, 2022, 39 : 5433 - 5452Gentry KingStacie IttershagenLuyang HeYing ShenFrank LiReginald Villacorta